AIM ImmunoTech Announces Late Breaking Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting

Rhea-AI Summary

AIM ImmunoTech (NYSE American: AIM) announced that data from a completed Phase 2 cisplatin-resistant advanced recurrent ovarian cancer study using Ampligen (rintatolimod) was accepted as a late‑breaking abstract for presentation at the 40th Annual SITC Meeting (November 5-9, 2025) in National Harbor, MD.

Poster details: Title: A Phase II Trial of Combination Locoregional Chemoimmunotherapy in Recurrent Platinum-Sensitive Ovarian Cancer Triggers a T Lymphotactic Response Correlating with Clinical Outcomes; Presenting author: Mackenzy M. Radolec, MD; Abstract #1343; Date: Friday, November 7, 2025; Location: Prince George ABC Exhibit Halls, Gaylord National Resort and Convention Center.

OCALA, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that data from the completed Phase 2 cisplatin-resistant advanced recurrent ovarian cancer clinical study utilizing Ampligen^® (rintatolimod) was accepted in a late-breaking abstract at the 40^th Annual SITC Meeting being held November 5-9, 2025 at National Harbor, MD.

Details of the poster presentation are as follows:

Title: A Phase II Trial of Combination Locoregional Chemoimmunotherapy in Recurrent Platinum-Sensitive Ovarian Cancer Triggers a T Lymphotactic Response Correlating with Clinical Outcomes
Presenting Author: Mackenzy M. Radolec, MD, Clinical Assistant Professor, Department of Obstetrics, Gynecology and Reproductive Sciences, UPMC Magee-Women’s Hospital
Abstract Number: 1343
Date: Friday, November 7, 2025
Location: Prince George ABC Exhibit Halls, Gaylord National Resort and Convention Center

For more information about the SITC Annual Meeting, please visit sitcancer.org.

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen^® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.

For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.

Cautionary Statement:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “continue,” “believe,” “potential,” “upcoming” and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Data, pre-clinical success and clinical success seen to date do not guarantee that Ampligen will be approved as a therapy for any indication. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.

Investor Contact:

JTC Team, LLC
Jenene Thomas
908.824.0775
AIM@jtcir.com

FAQ

What did AIM (AIM) announce about the SITC 2025 meeting on November 4, 2025?

AIM said a late‑breaking abstract of Phase 2 data using Ampligen in cisplatin‑resistant advanced recurrent ovarian cancer was accepted for presentation at SITC 2025.

When and where will AIM's abstract (Abstract #1343) be presented at the SITC meeting?

Abstract #1343 will be presented on Friday, November 7, 2025 at Prince George ABC Exhibit Halls, Gaylord National Resort and Convention Center, National Harbor, MD.

Who is the presenting author for AIM's Ampligen ovarian cancer poster at SITC 2025?

The presenting author is Mackenzy M. Radolec, MD, Clinical Assistant Professor, UPMC Magee‑Women’s Hospital.

What is the clinical focus of the AIM ImmunoTech abstract at SITC (AIM)?

The abstract reports Phase 2 trial data on combination locoregional chemoimmunotherapy with Ampligen in recurrent platinum‑sensitive/ cisplatin‑resistant ovarian cancer and a T lymphotactic response correlated with outcomes.

How can investors find more information about the SITC Annual Meeting where AIM will present?

Investors can visit sitcancer.org for meeting schedules, session details, and presenter information.